Your browser doesn't support javascript.
loading
Severe type I interferonopathy and unrestrained interferon signaling due to a homozygous germline mutation in STAT2.
Duncan, Christopher J A; Thompson, Benjamin J; Chen, Rui; Rice, Gillian I; Gothe, Florian; Young, Dan F; Lovell, Simon C; Shuttleworth, Victoria G; Brocklebank, Vicky; Corner, Bronte; Skelton, Andrew J; Bondet, Vincent; Coxhead, Jonathan; Duffy, Darragh; Fourrage, Cecile; Livingston, John H; Pavaine, Julija; Cheesman, Edmund; Bitetti, Stephania; Grainger, Angela; Acres, Meghan; Innes, Barbara A; Mikulasova, Aneta; Sun, Ruyue; Hussain, Rafiqul; Wright, Ronnie; Wynn, Robert; Zarhrate, Mohammed; Zeef, Leo A H; Wood, Katrina; Hughes, Stephen M; Harris, Claire L; Engelhardt, Karin R; Crow, Yanick J; Randall, Richard E; Kavanagh, David; Hambleton, Sophie; Briggs, Tracy A.
Afiliación
  • Duncan CJA; Primary Immunodeficiency Group, Immunity and Inflammation Theme, Translational and Clinical Research Institute, Newcastle University, Newcastle upon Tyne, UK. christopher.duncan@ncl.ac.uk tracy.briggs@manchester.ac.uk sophie.hambleton@ncl.ac.uk.
  • Thompson BJ; Department of Infection and Tropical Medicine, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK.
  • Chen R; Primary Immunodeficiency Group, Immunity and Inflammation Theme, Translational and Clinical Research Institute, Newcastle University, Newcastle upon Tyne, UK.
  • Rice GI; Primary Immunodeficiency Group, Immunity and Inflammation Theme, Translational and Clinical Research Institute, Newcastle University, Newcastle upon Tyne, UK.
  • Gothe F; Division of Evolution and Genomic Sciences, School of Biological Sciences, University of Manchester, Manchester, UK.
  • Young DF; Primary Immunodeficiency Group, Immunity and Inflammation Theme, Translational and Clinical Research Institute, Newcastle University, Newcastle upon Tyne, UK.
  • Lovell SC; Department of Pediatrics, Dr. von Hauner Children's Hospital, University Hospital, Ludwig-Maximilians-Universität Munich, Munich, Germany.
  • Shuttleworth VG; School of Biology, University of St. Andrews, St. Andrews, UK.
  • Brocklebank V; Division of Evolution and Genomic Sciences, School of Biological Sciences, University of Manchester, Manchester, UK.
  • Corner B; Complement Therapeutics Research Group, Immunity and Inflammation Theme, Translational and Clinical Research Institute, Newcastle University, Newcastle upon Tyne, UK.
  • Skelton AJ; Complement Therapeutics Research Group, Immunity and Inflammation Theme, Translational and Clinical Research Institute, Newcastle University, Newcastle upon Tyne, UK.
  • Bondet V; Complement Therapeutics Research Group, Immunity and Inflammation Theme, Translational and Clinical Research Institute, Newcastle University, Newcastle upon Tyne, UK.
  • Coxhead J; Primary Immunodeficiency Group, Immunity and Inflammation Theme, Translational and Clinical Research Institute, Newcastle University, Newcastle upon Tyne, UK.
  • Duffy D; Immunobiology of Dendritic Cells, Institut Pasteur, Paris, France.
  • Fourrage C; Genomics Core Facility, Biosciences Institute, Newcastle University, UK.
  • Livingston JH; Immunobiology of Dendritic Cells, Institut Pasteur, Paris, France.
  • Pavaine J; Plateforme Bioinformatique, Institut Imagine, Paris, France.
  • Cheesman E; Department of Paediatric Neurology, Leeds General Infirmary, Leeds, UK.
  • Bitetti S; Academic Unit of Paediatric Radiology, Royal Manchester Children's Hospital, Central Manchester University Hospitals NHS Foundation Trust, Manchester, UK.
  • Grainger A; Division of Informatics, Imaging and Data Sciences, School of Health Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester, UK.
  • Acres M; Department of Paediatric Histopathology, Central Manchester University Foundation NHS Trust, Manchester, UK.
  • Innes BA; Department of Paediatric Histopathology, Central Manchester University Foundation NHS Trust, Manchester, UK.
  • Mikulasova A; Primary Immunodeficiency Group, Immunity and Inflammation Theme, Translational and Clinical Research Institute, Newcastle University, Newcastle upon Tyne, UK.
  • Sun R; Primary Immunodeficiency Group, Immunity and Inflammation Theme, Translational and Clinical Research Institute, Newcastle University, Newcastle upon Tyne, UK.
  • Hussain R; Primary Immunodeficiency Group, Immunity and Inflammation Theme, Translational and Clinical Research Institute, Newcastle University, Newcastle upon Tyne, UK.
  • Wright R; Primary Immunodeficiency Group, Immunity and Inflammation Theme, Translational and Clinical Research Institute, Newcastle University, Newcastle upon Tyne, UK.
  • Wynn R; Complement Therapeutics Research Group, Immunity and Inflammation Theme, Translational and Clinical Research Institute, Newcastle University, Newcastle upon Tyne, UK.
  • Zarhrate M; Immunobiology of Dendritic Cells, Institut Pasteur, Paris, France.
  • Zeef LAH; Division of Evolution and Genomic Sciences, School of Biological Sciences, University of Manchester, Manchester, UK.
  • Wood K; Manchester Centre for Genomic Medicine, St Mary's Hospital, Manchester University Hospitals NHS Foundation Trust, Manchester, UK.
  • Hughes SM; Department of Paediatric Blood and Marrow Transplant, Royal Manchester Children's Hospital, Oxford Rd., Manchester, UK.
  • Harris CL; Genomics Core Facility, Institut Imagine, Paris, France.
  • Engelhardt KR; Bioinformatics Core Facility, Faculty of Biology, Medicine and Health, University of Manchester, Manchester, UK.
  • Crow YJ; Department of Pathology, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK.
  • Randall RE; Immunology Department, Royal Manchester Children's Hospital, Manchester University Hospitals NHS Foundation Trust, Manchester, UK.
  • Kavanagh D; Complement Therapeutics Research Group, Immunity and Inflammation Theme, Translational and Clinical Research Institute, Newcastle University, Newcastle upon Tyne, UK.
  • Hambleton S; Primary Immunodeficiency Group, Immunity and Inflammation Theme, Translational and Clinical Research Institute, Newcastle University, Newcastle upon Tyne, UK.
  • Briggs TA; MRC Institute of Genetics and Molecular Medicine, Centre for Genomic and Experimental Medicine, The University of Edinburgh, Edinburgh, UK.
Sci Immunol ; 4(42)2019 12 13.
Article en En | MEDLINE | ID: mdl-31836668
ABSTRACT
Excessive type I interferon (IFNα/ß) activity is implicated in a spectrum of human disease, yet its direct role remains to be conclusively proven. We investigated two siblings with severe early-onset autoinflammatory disease and an elevated IFN signature. Whole-exome sequencing revealed a shared homozygous missense Arg148Trp variant in STAT2, a transcription factor that functions exclusively downstream of innate IFNs. Cells bearing STAT2R148W in homozygosity (but not heterozygosity) were hypersensitive to IFNα/ß, which manifest as prolonged Janus kinase-signal transducers and activators of transcription (STAT) signaling and transcriptional activation. We show that this gain of IFN activity results from the failure of mutant STAT2R148W to interact with ubiquitin-specific protease 18, a key STAT2-dependent negative regulator of IFNα/ß signaling. These observations reveal an essential in vivo function of STAT2 in the regulation of human IFNα/ß signaling, providing concrete evidence of the serious pathological consequences of unrestrained IFNα/ß activity and supporting efforts to target this pathway therapeutically in IFN-associated disease.
Asunto(s)

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Interferón Tipo I / Factor de Transcripción STAT2 / Enfermedades del Sistema Inmune Límite: Humans / Infant / Male Idioma: En Revista: Sci Immunol Año: 2019 Tipo del documento: Article

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Interferón Tipo I / Factor de Transcripción STAT2 / Enfermedades del Sistema Inmune Límite: Humans / Infant / Male Idioma: En Revista: Sci Immunol Año: 2019 Tipo del documento: Article